Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
Relmada Therapeutics (Nasdaq: RLMD) will host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss fourth-quarter results for the period ended December 31, 2025 and recent business progress.
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) will host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss fourth-quarter results for the period ended December 31, 2025 and recent business progress.
Participant dial-ins are provided for US and international callers, and a replay will be available in the Investors section of the Relmada website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RLMD
On Mar 12, the day this news came out, RLMD closed 2.69% below the previous close.
Data tracked by StockTitan Argus for the Mar 12 session.
Key Figures
- Earnings call date
- March 19, 2026
- Fourth quarter 2025 results conference call
- Earnings call time
- 4:30 PM ET
- Start time for Q4 2025 results call
- US dial-in
- 1-877-407-0792
- Participant dial-in number (US)
- International dial-in
- 1-201-689-8263
- Participant dial-in number (International)
- Quarter reported
- Fourth quarter 2025
- Period ending December 31, 2025
- Quarter end date
- December 31, 2025
- End of reporting period for upcoming results
Previous Earnings date Reports
-
Announced date and time for Q3 2025 earnings call and webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
central nervous system disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss financial results for the fourth quarter ended December 31, 2025, and recent business progress.
Conference Call and Webcast Information:
- Date: Thursday, March 19, 2026 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.